Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Healthy Workers' COVID antibodies tracked for a year

NCT ID NCT04369066

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 24, 2026 · Last updated Jun 26, 2026 · Updated 1 time

Summary

This completed study followed nearly 2,000 healthy employees from Institut Curie and Institut Pasteur to see how their immune systems responded to the SARS-CoV-2 virus over time. Participants gave blood samples at four points over a year to test for antibodies. The goal was to learn how long antibodies last and how common past infection was in this group.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

What this could lead to
If successful, this study could help us understand how long COVID-19 antibodies last in healthy people and improve future testing strategies.
What could go wrong
This is an observational study, not a treatment trial. It only measures antibodies and cannot determine protection from infection or severe disease.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

1,971 people

The number who actually took part.

Started

Apr 2020

Finished

May 2022

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. Person, adult volunteer outside of any acute infectious episode with SARS-CoV-2\* (see paragraph indication), working at the Institute Curie and able to exercise their professional activity on one of the 3 sites of the Institute Curie: Paris, Orsay or Saint Cloud, or on the Campus of the Institute Pasteur. 2. Person aged 18 or over. 3. Information and consent of the person to the procedures related to the study (cf. information note / consent). From November 2020, person having presented at least one of the following criteria since January 2020: * A positive diagnostic test for SARS-COV-2 by PCR on a nasopharyngeal sample or antigenic test, * A positive SARS-CoV-2 serology, * An anosmia or / and an ageusia, * A respiratory infection \*\* associated with digestive signs \*\* whatever the working methods during confinement \* Subjects who are not showing active SARS-CoV-2 infection are considered volunteers at the time of inclusion: people with no clinical signs \*\* suggestive of SARS-CoV-2 infection at the time of collection or having had an end of symptoms for more than 7 days \[1\]. \*\* fever, fatigue, cough, shortness of breath, difficulty to breath, loss of taste or smell, headache, body aches, conjunctivitis or cold, digestive problems (vomiting, diarrhea), whether or not the signs led to sick leave, treatment and / or hospitalization \[2\]. Exclusion Criteria: * Declaration by the subject of signs suggestive of Coronavirus Infectious Disease 2019 (COVID-19) infection with SARS-CoV-2 in progress or for which the end of symptoms dates from less than 7 days * Inability to submit to study monitoring for geographic, social or psychological reasons

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Volunteers from the institute curie and institute pasteur staff who are not showing active SARS-CoV-2 infection are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Institut Curie

    Paris, 75005, France

  • Institut Pasteur

    Paris, 75015, France